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Purpose: The pathophysiology of diabetic retinopathy involves leukocyte adhesion to retinal vasculature, early blood-
retinal barrier breakdown, capillary nonperfusion, and endothelial cell death. We investigated the involvement of tumor
necrosis factor α (TNF-α) in diabetes-related histopathological changes in two relevant rodent models.
Methods: In short-term studies, Long-Evans rats with streptozotocin–induced diabetes were treated with or without the
TNF-α inhibitor, etanercept. For long-term studies, tumor necrosis factor receptor I (TNF-RI)-deficient mice and TNF-
RII-deficient mice, as well as C57/Bl6 wild-type mice, were fed 30% galactose for up to 20 months. The retinal
histopathological alterations of hypergalactosemia were analyzed in trypsin digest preparations. Endothelial cell injury
and apoptosis in rat retinas were evaluated by propidium iodide, TUNEL, CytoDeath staining, and DNA fragmentation
ELISA. Caspase 3 and 8 activity was evaluated by immunoblotting and quantitative enzymatic activity assay.
Results: Etanercept suppressed caspase activation, retinal cell injury, and apoptosis in short-term diabetic rats. Pericyte
and endothelial cell loss were also reduced in long-term hypergalactosemic mice. Long-term studies demonstrated that
pericyte loss and endothelial cell loss were reduced in comparison to wild-type diabetic controls.
Conclusions: Our study identifies an important role for TNF-α in the pathogenesis of signature diabetic retinopathy
pathologies and demonstrates that etanercept can inhibit retinal cell death and long-term complication of diabetes. Taken
together, our results suggest that etanercept could prove beneficial in preventing both early and late vascular diabetic
complications.
Leukocyte adhesion to the diabetic retinal vasculature
results  in  early  blood-retinal  barrier  breakdown,  capillary
nonperfusion, endothelial cell injury, and cell death. We have
previously  shown  that  intercellular  adhesion  molecule-1
(ICAM-1) and the leukocyte integrin CD18 are required for
these processes [1,2]. We also demonstrated that leukocyte-
mediated  retinal  cell  apoptosis  is  among  the  earliest
pathological manifestations of diabetic retinopathy and results
in  the  formation  of  acellular-occluded  capillaries,
microaneurysms,  and  vascular  basement  membrane
thickening [3-6]. The diabetic eye responds to the progressive
vascular occlusions with an increase of vascular permeability,
leading to macula edema, or the formation of neovessels that
finally proliferate into the vitreous [3,4]. Various mediators,
such as vascular endothelial growth factor (VEGF) and tumor
necrosis factor-α (TNF-α), contribute to the upregulation of
the adhesive molecules of the endothelial cells and leukocytes.
Although the role of VEGF in the development of diabetic
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complications in the eye is well established, the role of TNF-
α is still unclear.
TNF-α  is  the  prototypical  member  of  a  family  of
cytokines that also include Fas ligand (FasL), CD40 ligand
(CD40L)  and  TNF-related  apoptosis  inducing  ligand
(TRAIL),  and  induce  apoptosis,  differentiation,  cell
activation,  and  inflammation  [7].  TNF-α  is  found  in  the
extracellular  matrix,  endothelium,  and  vessel  walls  of
fibrovascular  tissue  of  proliferative  diabetic  retinopathy
(PDR) [8] and is elevated in the vitreous from eyes with this
complication [9,10]. The susceptibility to diabetic retinopathy
has been associated with TNF-α gene polymorphism [11] and
expression  of  human  leucocyte  antigen  (HLA)-DR3  and
HLA-DR4  phenotypes  and  HLA-DR4  phenotypes.  The
involvement  of  TNF-α  in  the  pathogenesis  of  diabetic
retinopathy  [8,12,13]  could  be  attributed,  in  part,  to  its
proinflammatory activity. Indeed, we have demonstrated that
TNF-α is elevated in the diabetic retina and that the soluble
p75-Fc  fusion  protein  (etanercept)  suppresses  leukocyte
adhesion in diabetic retinal arterioles, venules, and capillaries,
as well as blood-retinal barrier breakdown in a rat model of
diabetic retinopathy [14].
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1418TNF-α is a potent inducer of endothelial cell apoptosis
[15,16]. Yet, its role in regulating endothelial cell apoptosis
in diabetic retinopathy has not been studied. Our previous
results  have  demonstrated  a  mechanism  of  leukocyte-
mediated endothelial cell death depending on the TNF-related
ligand  FasL  [17].  We  now  show  that  the  soluble  TNF-α
inhibitor  etanercept  significantly  reduces  retinal  cell
apoptosis,  caspase  activation  and  long-term  complications
during the course of diabetes in the eye. Our data identify
TNF-α as a key molecule in the pathogenesis of the early
signature pathologies and later diabetic complications that
characterize diabetic retinopathy.
METHODS
Animals: Male Long-Evans rats purchased from Jackson Labs
(Bar Harbor, ME) weighing approximately 200 g at an age of
6 weeks were used. The animals were fed standard laboratory
chow and allowed free access to water in an air-conditioned
room  with  a  12h:12h  light-dark  cycle.  Unless  otherwise
stated, the animals were anesthetized with 40 mg/kg ketamine
(Ketalar;  Parke-Davis,  Morris  Plains  NJ)  and  4  mg/kg
xylazine (Rompun, Bayer Leverkusen, Germany) before all
experiments. For long-term experiments, mice deficient for
TNF-α  receptor  protein  55  (Rp55;  Rp55−/−,  B6.129-
Tnfrsf1atm1Mak/J),  and  Rp75  (Rp75−/−,  B6.129S2-
Tnfrsf1btm1Mwm/J) were used (Jackson Laboratory, Bar Harbor,
ME).  Age-matched  C57BL/6J  mice  served  as  controls.
Rp55−/−  and  Rp75−/−  mice  possess  normal  retinas  and  are
markedly  hypomorphic  rather  than  null  alleles  for  tumor
necrosis factor receptor I (TNF-RI)-deficient mice and TNF-
RII. Animal care guidelines comparable to those published by
the Institute for Laboratory Animal Research (Guide for the
Care and Use of Laboratory Animals) were followed and were
approved by the Animal Care and Use Committee of the
Regierungspräsidium, Köln, Germany.
Rat model of streptozotocin-induced diabetes: Animals were
allowed to undergo a 12 h fast, following which they received
a single 60 mg/kg intraperitoneal injection of streptozotocin
(STZ; Sigma, St. Louis, MO) in 10 mM sodium citrate buffer,
pH 4.5 or citrate buffer alone. Then 24 h later, animals with
blood glucose levels higher than 250 mg/dl were considered
diabetic.  In  vivo  experiments  were  performed  two  weeks
following STZ injection, and blood glucose was measured
again before the onset of the experiments. In previous studies,
we had demonstrated that STZ nonconverters do not differ in
term  of  gene  expression,  amount  of  blood-retinal  barrier
breakdown, or leukostasis from nondiabetic controls [18].
Thus, in the current study nondiabetic animals with confirmed
glucose levels of less than 120 mg/dl were used as controls.
Mouse model of galactosemia: Experimental galactosemia
was  produced  by  feeding  Rp55−/−  and  Rp75−/−  mice  and
respective  controls  a  diet  of  Teklad  7004  (Harlan,  WI)
enriched with 30% D-galactose as previously described [4,
19]. This results in hyperglycemia largely devoid the attendant
metabolic  abnormalities  associated  with  diabetes.
Bodyweight was measured weekly. The level of the blood
hexose elevation was estimated by measuring the levels of
nonenzymatic  hemoglobin  A1c  (HbA1c)  using  affinity
chromatography (Glyc-Affin, Pierce, Rockford, Il). Mice with
HbA1c of ≥6% in repeated measurements were considered
galactosemic and included in the study. Using this animal
model, we recently demonstrated a central role of adherent
leukocytes in the pathogenesis of diabetic retinopathy [19].
Treatment with a soluble TNF-α receptor: Soluble p75 TNF-
α receptor/Fc fusion protein (Enbrel™, etanercept; Wyeth-
Pharma GmbH, Münster, Germany) was reconstituted with
sterile  water  according  to  the  manufacturer’s  instructions.
Starting one day after the STZ treatment, confirmed diabetic
rats were randomized to receiving either etanercept or solvent
alone. The drug was administered subcutaneously. The dose
was  0.3  mg/kg  at  three  times  per  week  according  to  the
recommendation  of  the  manufacturer  for  treatment  of
rheumatoid arthritis in humans and according to our previous
studies in the rat model [14,20-22]. For each experiment, a
minimum of n=6 animals per treatment group were used.
Propidium  iodide  labeling  in  vivo:  Dead  and  injured
endothelial cells were labeled in vivo using propidium iodide
(PI; Molecular Probes, Eugene, OR). Following the induction
of  deep  anesthesia  with  50  mg/kg  intraperitoneal  sodium
pentobarbital, 1 mg/ml PI in PBS (140 mM NaCl, 10 mM
NaH2PO4, pH 7.4) was injected intravenously via the tail vein
at  a  concentration  of  5  µmol/kg  (0.668  ml/200  mg
bodyweight). After fixation by intracardiac perfusion with 1%
paraformaldehyde in PBS labeling with concanavalin A-lectin
was performed as described before [2,19]. The identification
of  arterioles,  venules,  and  capillaries  was  done  based  on
morphological criteria. Venules are usually slightly larger
than arterioles, and capillaries have the smallest diameter.
Labeled  endothelial  cells  were  distinguished  from
surrounding cells, especially pericytes, by distinct cellular
outline and nuclear shape of the endothelial cells on retinal
flat mounts. All experiments were performed in a masked
fashion.
DNA fragmentation ELISA: A cellular DNA fragmentation
ELISA was used to determine cell death quantitatively (Roche
Diagnostics,  Mannheim,  Germany).  This  ELISA  detects
apoptotic fragmentation in BrdU-labeled DNA. Within 24 h
after the last injection of either etanercept or the solvent, the
assay was performed as described [17]. Briefly, the animals
received a single i.p. injection of 20 mg/kg BrdU. Retinae
were excised 24 h after injection of the BrdU, lysed in buffer
(4 M urea,100 mM Tris, 20 mM NaCl, 200 mM EDTA, pH
7.4), and incubated with 4 mg/ml proteinase K at 55 °C.
Genomic DNA fragments were isolated using the Apoptotic
DNA ladder kit (Roche Diagnostics, Mannheim, Germany)
according to the manufacturer’s instructions and finally eluted
in  100  µl  of  elution  buffer  per  retina.  The  amount  of
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1419fragmented  DNA  that  corresponded  to  each  eluate,  and
therefore to each retina, was subsequently quantified using the
DNA fragmentation ELISA (Roche Diagnostics) according to
the manufacturer’s instructions. Photometric readings were
obtained at 450 nm.
Terminal  transferase  dUTP  nick  end  labeling  and  M30
staining: Whole eyes from normal and diabetic rats treated
with  either  etanercept  or  vehicle  were  fixed  in  4%
paraformaldehyde overnight at 4 °C and embedded in paraffin
using standard histological procedures. Terminal Transferase
dUTP nick end labeling (TUNEL) staining was performed in
tissue sections as previously described [17,23,24] using the
TUNEL kit (Roche Diagnostics). Briefly, DNA fragments in
the tissue sections were labeled with digoxigenin-nucleotide
and  then  allowed  to  bind  an  anti-digoxygenin  antibody
conjugated to a rhodamine reporter molecule. Apoptotic cells
were detected using a CD-330 charge-coupled device (CCD)
camera (Dage-MIT, Michigan, IN) attached to a Leica MZ
FLIII microscope (Leica Microsystems, Deerfield, IL). The
images  were  captured  on  an  Apple  (Cupertino,  CA)  G4
Computer  and  analyzed  using  Openlab  software
(Improvision,  Lexington,  MA).  The  number  of  positive
endothelial cells was quantified by calculating the ratio of
positive endothelial cells to negatively stained endothelial
cells in retinal vessels. This was done in each of 12 sections
from different eyes and expressed as percentage of positive
cells.
Cytokeratin 18 is cleaved by caspases in early apoptotic
events.  The  M30  CytoDeath  antibody  (Boehringer
Mannheim) is a monoclonal mouse IgG2b antibody that binds
to  a  caspase  cleaved  formalin  resistant  epitope  of  the
cytokeratin  18  (CK18)  cytoskeletal  proteins.
Immunoreactivity of the M30 antibodies is confined to the
cytoplasm of apoptotic cells. It allows the determination of
caspase-related  enzymatic  activity  early  in  the  course  of
apoptosis.
M30  Cytodeath  immunoreactivity  was  evaluated  as
described  [17,25].  In  brief,  5  μm  paraffin  sections  were
deparaffinised, rehydrated, micro waved for 5 min in Dako
antigen retrieval solution (Carpinteria, CA), treated for 30 min
in methanol containing 0.5% H2O2, and then incubated for 1
h in incubation buffer (PBS containing 1% BSA and 0.1%
Tween-20). The M30 CytoDeath antibody was applied for 1
h at room temperature in a 1:50 dilution in incubation buffer.
The sections were subsequently washed in PBS containing
0.1% Tween-20 and incubated with an anti-fluorescein-POD
(horse-radishperoxidase)  antibody  (Roche  Diagnostics)
according to the manufacturer’s instructions. The peroxidase
reaction  was  developed  with  DAB  (3,3-diaminobenzidine
tetrahydrochloride), and the slides were counterstained with
hematoxylin.
Western blot analysis for caspase 3 and caspase 8: The levels
of  protein  expression  of  caspase  3  and  caspase  8  were
evaluated  by  western  blotting,  performed  as  described
previously [25,26]. Briefly, whole retinas were lysed for 30
min on ice in lysis buffer (50 mM Tris-HCl, pH 8, with
120 mM NaCl and 1% NP-40), supplemented with a mixture
of proteinase inhibitors (Complete Mini; Roche Diagnostics).
The samples were cleared by microcentrifugation (13,800x g,
30 min, 4 °C) and assessed for protein concentration. Thirty
micrograms of protein per sample was electrophoresed in a
12%  sodium  dodecyl  sulfate  (SDS)-polyacrylamide  gel
(SDS–PAGE),  and  electroblotted  onto  nitrocellulose
membranes. After a 1 h incubation in blocking solution (20%
IgG-free normal horse serum, in PBS), the membranes were
exposed overnight at 4 °C to an anti-caspase-3 antibody (Santa
Cruz  Biotechnology,  Heidelberg,  Germany)  or  an  anti-
caspase-8  antibody  (Upstate  Biotechnology,  Lake  Placid,
NY).  After  washing  in  PBS,  the  respective  secondary
peroxidise-labeled antibody was applied at 1:10,000 dilution
for 1 h at room temperature. The proteins were visualized with
the  enhanced  chemiluminescence  technique  (ECL  kit,
Amersham  Pharmacia  Biotech,  Piscataway,  NJ).  Protein
loading  was  assessed  by  β-actin  immunostaining  and
Coomassie staining of the membrane.
Enzymatic activity of caspase 3 and caspase 8: The activity
of caspase 3 and caspase 8 was measured by a colorimetric
analysis of the enzymatic conversion of a specific substrate as
described [17]. The activity of caspases 3 and 8 was measured
via the enzymatic conversion of a specific substrate. In brief,
retinas  were  lysed  in  a  buffer  containing  20  mM  PIPES,
100 mM NaCl, 10 mM DTT, 1 mM EDTA, 0.1% CHAPS,
and  10%  sucrose,  pH  7.2.  After  centrifugation  of  the
homogenates at 13,800x g rpm for 10 min, 40 µl aliquots of
the supernatants were pipetted into 96 well plates. Excess
amounts (80 µl) of caspase 8 substrate (Bachem Biochemica
GmbH, Heidelberg, Germany) or caspase 3 substrate (Alexis
Biochemicals,  Grünberg,  Germany)  were  added  to  the
supernatants.  The  reaction  product  was  quantified  by
fluorophotometry on a plate reader (Beckmann, Hamburg,
Germany) at 480 nm after 1, 2, 5, and 15 min (caspase 3) or
1,  60,  120,  and  180  min  (caspase  8).  The  results  were
normalized to total protein per sample as determined by the
Bradford assay (Bio-Rad, Munich, Germany).
Trypsin digests of the retinal tissue: Trypsin digestion of the
retina was performed according to the method of Cogan et al.
[27]  with  some  modification  [19,28].  Formaldehyd-fixed
retinas were divided at the optic disk into four quadrants. The
retinal tissue was incubated in 3% Trypsin, 0.1 M Tris (pH
7.8) for 1–3 h at 37 °C until the medium became cloudy and
the tissues showed signs of disintegration. The retinas were
than transferred to water and shaken gently to free the vessel
network from adherent retinal tissue, washed in fresh water,
mounted on glass slides and allowed to dry. They were stained
with  hematoxylin.  Endothelial  cells  have  large,  ellipsoid
nuclei  lying  within  the  vessel  wall  along  the  axis  of  the
capillaries whereas pericytes nuclei are smaller, darker and
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wall. Mice that were diabetic for 11, 16, or 20 months were
used. A digital imaging system was used to analyze four
quadrants per retina for histopathological changes, including
acellular capillary microaneurysm formation, and these were
then grouped together. Four retinas per group were analyzed.
All measurements were performed in a masked fashion.
Statistical analysis: All results are expressed as the mean
±standard  deviation  (SD).  The  data  were  compared  by
ANOVA with post hoc comparisons tested by using Fisher’s
protected least significant difference procedure. The data of
the quantitative PCR were analyzed by Whitney-Mann-U-
test.  Differences  were  considered  statistically  significant
when p values were less than 0.05.
RESULTS
Etanercept reduces diabetes-induced retinal endothelial cell
injury: To investigate the role of TNF-α in mediating retinal
endothelial  cell  death  in  early  diabetic  retinopathy,  we
assessed the effect of etanercept on retinal endothelial injury
using  a  PI  labeling  assay  as  previously  described  [2].
According to our previously published data, two weeks after
induction of diabetes the amount of PI-labeled cells increased
significantly compared to nondiabetic controls. PI-positive
cells were mainly located in clusters, which were found in the
capillaries,  venules,  and  arterioles  (Figure  1).  The  total
number of PI-positive cells per retina was 7.46±7.14 (n=13)
in  nondiabetic  control  animals  compared  to  83.54±16.02
(n=13; p<0.0001) in diabetic animals. Treatment of diabetic
animals with etanercept resulted in a 39.5% reduction of PI-
positive cells (50.46±9.48 PI positive cells per retina; n=13;
p<0.0001) compared to diabetic animals without treatment. In
nondiabetic animals, there was no significant change in the
number of PI-positive cells after treatment with etanercept
(7.23±7.00 PI positive cells per retina; n=13, p>0.05).
Etanercept reduces diabetes-induced apoptosis in the retina:
To quantify the apoptotic cell death in the retina, we used a
modified ELISA for fragmented DNA (Figure 2). Two weeks
after induction of diabetes with STZ, fragmented DNA had
increased twofold (0.13 ± 0.01 versus 0.26±0.07 arbitrary
units;  n=6;  p<0.0001)  when  compared  to  the  controls.
Systemic  treatment  with  the  TNF-α  inhibitor  etanercept
reduced fragmented retinal DNA by half (0.11±0.01; n=6;
p<0.0001), resulting in levels comparable to the nondiabetic
controls.
Etanercept reduces diabetes-induced retinal endothelial cell
apoptosis: To localize the apoptotic cell death within the
retina, we stained formalin-fixed, paraffin-embedded retinal
sections  by  using  TUNEL  assay  (Figure  3)  and  M30
CytoDeath  antibody  (Figure  4).  TUNEL  staining  labels
fragmented DNA that is localized in the nucleus, whereas
M30 stains caspase-cleaved cytokeratins that are located in
the cytoplasm. Almost no TUNEL positivity or M30 staining
was detected anywhere in the retina in nondiabetic animals
with or without etanercept treatment (Figure 3 and Figure 4).
In two-week diabetic animals, TUNEL-positive and M30-
positive  cells  were  located  predominantly  in  the  vascular
endothelium of the retinal vessels as well as in the inner
nuclear layer. Few positive cells were found in the ganglion
layer. Treatment with etanercept was able to reduce TUNEL
and M30 staining throughout the retina in diabetic animals
(Figure 4).
To quantify the amount of apoptotic cell death in the
retinal vessels, we determined the ratio of TUNEL-positive
endothelial cells or M30-positve cells to the total number of
endothelial cells in cross-sections of 12 distinct eyes from
Figure  1.  Quantification  of  endothelial  cell  injury  and  death  by
propidium iodide staining. Dead and injured retinal endothelial cells
were labeled in vivo using propidium iodide. Endothelial cell damage
was increased in diabetic animals in capillaries (A), venules (B), and
arteries  (C).  Administration  of  the  TNF-α  inhibitor  etanercept
reduced diabetes-induced endothelial cell injury in all vessel types.
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1421each of six animals per group. After two weeks of diabetes,
the ratio of TUNEL-positive cells increased 6.2 fold when
compared to nondiabetic control animals (n=12; p<0.0001).
Treating  diabetic  animals  with  etanercept  reduced  the
TUNEL-positive  staining  by  one-third  (n=12;  p<0.0001;
Figure 3). Similarly, M30 staining was rare in the endothelial
cells of nondiabetic control animals, however, the ratio of
M30-positve  cells  increased  8.9  fold  after  a  two-week
duration of diabetes (n=12; p<0.0001). The percentage of
M30-positive endothelial cells was reduced by 41% (n=12;
p<0.0001) after inhibition of TNF-α activity with etanercept
(Figure 4). These results correlate with the data analyzing PI
positivity as demonstrated in the previous section.
Inhibited  caspase  activation  by  Etanercept  in  diabetic
retinopathy:  The  increase  in  M30  staining  observed  in
diabetic  retinas  suggested  the  involvement  of  caspases  in
mediating apoptotic cell death. During apoptosis, caspases are
activated in a hierarchical manner to cleave structural and
functional proteins needed for cell survival. Cleaved products
for both caspase 8 and caspase 3 were found by western blot
analysis  in  the  retinal  lysates  of  rats  after  two  weeks  of
diabetes,  proving  the  activation  of  these  caspases  in  the
diabetic  retina  in  the  rat  (Figure  5  and  Figure  6).
Administration of the soluble TNF-α inhibitor in the diabetic
rats significantly reduced the cleaved forms for both caspase
8 (14 kDa band; Figure 5) and caspase 3 (17 kDa band; Figure
6), an observation that correlates with the reduced levels of
apoptotic cells in these rats as described above. Furthermore,
the ability of these caspases to cleave their specific substrates
was tested directly in the retinal lysates. Caspase 3 was found
to  cleave  its  substrate  efficiently  as  early  as  1  min  after
incubation.  In  comparison  to  nondiabetic  animals,  the
substrate conversion rate was 2.16-fold higher in the diabetic
retinas (322.69±99.71 versus 149.73±54.51 arbitrary units;
n=3; p<0.001). Treatment of diabetic animals with etanercept
reduced the conversion rate to 262.01±74.9 (n=3; p=0.061).
Figure 2. Cellular DNA fragmentation ELISA in the retina. DNA
fragmentation and therefore apoptosis was significantly increased in
the  retinal  tissue  of  diabetic  compared  to  nondiabetic  animals.
Treatment with etanercept reduced the diabetes-induced increase in
DNA fragmentation.
Caspase 8 activity was measured 180 min after incubation
with the substrate. In comparison to nondiabetic animals, the
substrate conversion rate was 2.28 fold higher in the diabetic
retinas (37.63 ± 21.6 versus 85.80 ± 23.7 arbitrary units; n=3;
p<0.0005).  Treatment  of  diabetic  animals  with  etanercept
reduced the conversion rate to 65.94 ± 14.35 (n=3; p=0.047).
Histopathological capillary changes in long-term galactose-
fed mice: To achieve an extended observation period, we
investigated galactose-fed mice, which demonstrate similar
histopathological  changes  as  diabetic  animals  [19].  With
galactose feeding we were able to analyze trypsin digests of
the  retinas  in  11-month-,  16-month-,  and  20-month-old
galactosemic mice and age-matched controls fed with regular
laboratory chow, respectively.
Hypergalactosemia reduced the number of endothelial
cells in all of the three mouse strains (Figure 7 A). Endothelial
cells  decreased  by  15%  after  11  months,  by  7%  after  16
months and by 38% after 20 months in hypergalactosemic
wild-type mice as compared to non-galactosemic controls.
However, TNF-α receptor deficiency protected against
endothelial  cell  loss.  In  both  galactosemic  Rp55−/−  and
Figure 3. TUNEL staining of retinal sections. Paraffin sections of
eyes  from  nondiabetic  rats  (A),  nondiabetic  rats  treated  with
etanercept  (B),  diabetic  rats  (C),  and  diabetic  rats  treated  with
etanercept  (D)  were  assessed  by  TUNEL.  Sections  were
subsequently  counterstained  with  hematoxylin.  Insert  shows  an
overview of a diabetic retina with the ganglion cell layer (above), the
inner nuclear layer (middle, light blue) and the outer nuclear layer
(below,  dark  blue).  Numbers  of  positive  endothelial  cells  were
counted in each of 12 sections and expressed as percent of total
endothelial  cells.  Treatment  with  etanercept  reduced  diabetes-
induced endothelial cell apoptosis, as detected by TUNEL staining.
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1422Rp75−/− mice the number of endothelial cells was significantly
higher than in galactosemic wild-type mice as counted after
15–16 months (100.2±9.8 and 93.8±4.0 versus 58.6±18.82;
p<0.001) and 18–20 months (90.6±6.3 and 95.8±6.8 versus
64,4±26.1; p<0.05) of hypergalactosemia. After 20 months of
galactosemia,  endothelial  cell  counts  in  Rp55−/−  mice  and
Rp75−/− mice did not differ significantly from age-matched
normal litter mates (90.6±6.3 versus 107±12.3 and 95.8+6.8
versus 96.6±7.2 (p>0.05).
The  number  of  pericytes  decreased  in  all  Rp55−/−,
Rp75−/−,  and  wild-type  mice  during  the  time  course  of
hypergalactosemia (Figure 7B). Maximal pericyte reduction
reached 30%, 23.9%, and 66.4% after 20 months. Again, cell
loss was smaller in TNFR-deficient mice when compared to
the wild-type mice. While no significant difference could be
detected  between  Rp55−/−  and  Rp75−/−  mice,  both  TNF-
deficient mouse strains showed less pericyte loss than wild-
type mice. The differences in number of pericytes between the
three groups were significant after both 16 months (35.6±4.2
Figure  4.  M30  CytoDeath  staining  of  retinal  sections.  Paraffin
sections of eyes from non-diabetic rats (A), non-diabetic rats treated
with etanercept (B), diabetic rats (C), and diabetic rats treated with
etanercept  (D)  were  assessed  with  M30  staining.  Sections  were
subsequently  counterstained  with  hematoxylin.  Insert  shows  an
overview of a diabetic retina with the ganglion cell layer (above), the
inner nuclear layer (middle, light blue) and the outer nuclear layer
(below,  dark  blue).  Numbers  of  positive  endothelial  cells  were
counted in each of 12 sections and expressed as percent of total
endothelial cells. Treatment with etanercept reduced endothelial cell
apoptosis and caspase activity as determined by M30 staining.
and  38.9±5.4  versus  14.6±2.1;  p<0.001)  and  20  months
(32.1±4.8 and 34.7±4.3 versus 15.2±6.0; p<0.01).
Furthermore, the formation of acellular capillaries per
retina was quantified as described previously [4,6,19,28]. In
all groups of animals fed with normal chow, five or fewer
acellular capillaries per retina were found: C57/BL6 3.25±0.5,
Rp55−/− 2.25±0.5, and Rp75−/− 2.5±0.57. In all strains, the
number of acellular capillaries increased with the duration of
galactose feeding. The number of acellular capillaries showed
an  approximately  ninefold  increase  after  20  months  of
hypergalactosemia  (Figure  7C)  and  a  decrease  in  TNFR-
deficient mice. Representative images of the capillary bed of
trypsin  digested  retinas  in  galactosemic  animals  and  age-
matched  controls  are  presented  in  Figure  8.  The  loss  of
endothelial  cells  and  pericytes  as  well  as  the  acellular
Figure 5. Caspase 8 enzymatic activity in rat retinas. A: The level of
protein expression of caspase 8 in the rat retina was evaluated by
western blotting. Diabetes increased the cleaved form of caspase 8
(activated  form),  whereas  treatment  with  etanercept  reduced  the
diabetes-induced cleavage of caspase 8. B: The enzymatic activity
of caspase 8 in the rat retina was evaluated by a colorimetric analysis.
Diabetes increased the activity of caspase 8 as measured by the
conversion  of  its  specific  substrate.  Treatment  with  etanercept
reduced the diabetes-induced caspase 8 activation and therefore the
conversion of its substrate and correlates with the reduction in the
cleaved form of the caspase as measured by the western blot shown.
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1423capillaries in the retinas of 16 months galactosemic animals
can be seen clearly.
DISCUSSION
In  the  current  study,  we  investigated  the  role  of  the
inflammatory cytokine TNF-α in the apoptotic cell death of
retinal endothelial cells during early and late stages of diabetic
retinopathy  using  a  rat  model  of  streptozotocin-induced
diabetes and a mouse model of long-term galactosemia.
Our  data  emphasize  the  role  of  TNF-α  in  signature
pathologies in both early and late diabetic retinopathy. We
have  previously  demonstrated  that  TNF-α  increases  early
during the course of diabetic retinopathy [14]. TNF-α is a pro-
inflammatory  cytokine  produced  mainly  by  monocytes,
macrophages,  activated  endothelial  cells,  fibroblasts,  and
joint cartilage chondrocytes [11]. The induction of TNF-α
Figure 6. Caspase 3 enzymatic activity in rat retinas. A: The level of
protein expression of caspase 3 in the rat retina was evaluated by
western blotting. Diabetes increased the cleaved form of caspase 3
(activated  form),  whereas  treatment  with  etanercept  reduced  the
diabetes-induced cleavage of caspase 3. B: The enzymatic activity
of caspase 3 in the rat retina was evaluated by a colorimetric analysis.
Diabetes increased the activity of caspase 3 as measured by the
conversion  of  its  specific  substrate.  Treatment  with  etanercept
reduced the diabetes-induced caspase 3 activation and therefore the
conversion of its substrate and correlates with the reduction in the
cleaved form of the caspase as measured by the western blot shown.
could be attributed to various conditions that operate in the
course  of  diabetes,  such  as  hyperglycemia  and  oxidative
stress,  and  inflammatory  cytokines  such  as  VEGF  or
interleukins, which activate the transcription factor NF-κB
[29,30]. We have previously demonstrated that treatment with
high doses of antiinflammatory agents, such as aspirin and the
selective  cyclooxygenase-2  (COX-2)  inhibitor  meloxicam,
reduces the levels of TNF-α in the diabetic retina, proving that
inflammatory  mediators  and  COX-2  are  central  in  the
upregulation of this cytokine [14].
Endothelial and pericyte cell loss is one of the earliest and
key manifestations of diabetic retinopathy. It leads to blood-
retinal barrier breakdown, formation of acellular capillaries,
microaneurysms,  and  retinal  ischemia  that  hallmark  the
transition to proliferative diabetic retinopathy. As we [17] and
others [31-34] have previously described, during the course
of diabetes, injury and apoptosis occur early in endothelial
cells,  retinal  ganglion  cells,  and  astrocytes.  Singh  et  al.
detected apoptosis in endothelial cells in microvessels three
days after the induction of diabetes [31], and Emanueli et al.
have shown that in the STZ model, endothelial cells die via
apoptosis as early as two weeks after the induction of diabetes
[32]. Mizutani et al. noted accelerated death of endothelial
Figure 7. Retinal histopathological changes were investigated in
galactosemic TNF-RI−/− and TNF-RII−/− mice and their respective
wild-type controls. Both the number of endothelial cells per field as
well as the number of pericytes per field significantly decreased
throughout the course of the disease in the wild-type galactosemic
animals (A, B). The number of acellular capillaries was significantly
increased at 20 months of galactosemia (C).
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1424cells in the retinas from diabetic patients [33], and Barber et
al. demonstrated increased neural cell death as early as one
month after the induction of diabetes in male Sprague-Dawley
rats [34]. In the current study, we found increased amounts of
DNA fragmentation in diabetic versus non-diabetic retinas,
confirming  the  increased  incidence  of  apoptosis,  and  we
localized this apoptotic activity in the endothelial, pericyte,
and ganglion cell layer. The same areas demonstrated staining
with the M30 antibody, indicating caspase activation, and
resulting in apoptotic death.
Caspases,  a  family  of  cysteine  proteases,  are  both
involved in activation of cytokines as well as in the initiation
and execution of apoptosis [35]. Initiator caspases such as
caspase 8, are known to activate proteolytically executioner
caspases, such as caspase 3 [36,37]. The activation of both the
Figure 8. Representative images of the capillary bed in galacosemic
animals and age-matched controls. Histopathological changes were
investigated in galactosemic TNF-RI−/− and TNF-RII−/− mice and
their respective wild-type controls by trypsin digestion of the retinas.
Representative images of the capillary bed of trypsin digested retinas
in age-matched controls (left column) and galactosemic animals
(right column) are shown.
initiator as well as the effector caspases in complete retinal
extracts was also shown. Our results correlate with Martin and
coworkers, who found activation of caspase 3 in cells of the
ganglion cells layer in diabetic retinas in a statistically higher
degree than in retinas from nondiabetic controls in the STZ
mouse model [38].
According to our data, all the aforedescribed pathologies,
including  cellular  loss,  TUNEL  reactivity,  and  caspase
activation are significantly reduced in the anti-TNF-α-treated
retinas. This leads us to the conclusion that TNF-α is a major
player in retinal cell death in diabetic retinopathy. TNF-α is
known to be a potent inducer of apoptosis in endothelial cells
[15,16]. TNF signal transduction is mediated through two cell
surface receptors, TNF-RI and TNF-RII. Until recently, it was
believed  that  TNF-induced  apoptosis  was  mediated
exclusively  by  TNF-RI  because  TNF-RII  lacks  the  death
domain. However, it has been demonstrated that TNF-RII
enhances  TNF-RI-mediated  apoptosis.  The  significant
inhibition of the diabetes-induced activation of caspase 8 and
3 in our model leads to the conclusion that TNF-α induces
retinal cell death in diabetes through these two caspases.
However, there might be also an indirect involvement for
TNF-α  in  diabetic  apoptotic  cell  death.  In  experimental
diabetes, adhesion of leukocytes to the retinal vasculature is
one of the earliest events and results in enhanced blood-retinal
barrier breakdown, endothelial injury, and cell death as well
as capillary nonperfusion [1,2]. As we have previously shown,
leukocyte-induced  apoptosis  is  mediated  by  the  Fas-FasL
pathway [17,23], and administration of soluble etanercept
reduced leukocyte adhesion [14]. Since sequestration of TNF-
α reduces retinal apoptosis, it is justified to hypothesize that
TNF-α  could  induce  apoptosis  indirectly  by  increasing
leukocyte adhesion. TNF-α has been shown to increase NF-
κB in many models, whereas NF-κB is a known regulator of
FasL expression. It is interesting to speculate that the early
rise in TNF-α expression in diabetes results in activation of
NF-κB that in turn upregulates FasL expression in leukocytes
[39]. Subsequently, these leukocytes are better equipped to
induce  Fas-mediated  apoptosis  in  their  targets  as
demonstrated previously [17]. During inflammation, TNF-α
and VEGF induce endothelial cell downregulation of FasL
and upregulate Fas and adhesion molecules such as ICAM-1
[40].  This  downregulation  of  FasL  in  the  endothelium,
combined  with  the  increased  apoptotic  threshold  of
leukocytes in diabetes [41], could result in a relative increase
of surviving leukocytes in immunoprivileged areas such as the
retina.  In  addition,  the  converse  upregulation  of  adhesion
molecules and Fas on the endothelium, and increases in FasL
on the leukocytes, could function together to drive the balance
toward  a  significantly  increased  leukocyte-induced
endothelial death in diabetes. This effect might be mediated
by circulating factors such as VEGF, TNF-α, or oxidative
stress. The activation of caspase 8 and caspase 3 in retinas of
diabetic rats according to our results and the reduction of this
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a TNF-α initiated receptor-mediated apoptosis.
In  this  study,  apoptosis  was  significantly  reduced  in
endothelial cells as well as in the inner nuclear layer in the
retinas of diabetic rats upon the administration of the TNF-α
inhibitor  and  the  concomitant  reduction  of  leukocyte
adhesion. This leads to the conclusion that leukocytes that
adhere  to  the  vasculature  might  be  responsible  for  the
observed  endothelial  apoptosis,  whereas  leukocytes
extravasating  to  the  retinal  tissue  are  responsible  for  the
apoptotic  death  observed  in  other  cell  layers.  This  is  in
accordance  with  our  previous  data  in  diabetes,  where
inhibition of leukocyte-mediated death by neutralizing FasL
reduced apoptotic death not only in the endothelial cell layer
but also in the ganglion and inner cell layer [17].
To establish a role for TNF-α in the pathogenesis of
signature lesions in diabetic retinopathy and to address the
question whether the demonstrated effects are only due to its
transient overexpression in early diabetes, we used a long-
term mouse model of diabetic retinopathy. The course of
diabetes in rodents includes the formation of signature lesions
similar  to  those  in  humans,  such  as  acellular  capillary
formation, microaneurysms breakdown of the blood-retinal
barrier,  and  macular  edema.  These  similarities  allow
extrapolating valuable conclusions from the rodent models of
long-term  diabetes  relevant  to  human  diabetes.  We  have
examined  the  vascular  pathology  in  a  mouse  model  of
galactose-induced diabetes that allows for the analysis of the
histopathological  alterations  up  to  two  years  after  the
induction of diabetes. We [19] and others [4] have found that
throughout  the  course  of  experimental  galactosemia  the
number  of  endothelial  cells  and  pericytes  decreased
significantly, whereas the formation of acellular capillaries
and microaneurysms increased [33]. Pericyte loss is in the
center  of  the  pathogenesis  of  diabetes,  allowing  for
microaneurysm formation possibly by local weakening and
out-pouching of the capillary wall, and contributing to the
endothelial  dysfunction  and  damage  that  leads  to  cellular
death  and  formation  of  acellular  capillaries.  Surprisingly
enough, the formation of acellular capillaries was not reduced
in  the  TNF-RI-  and  TNF-RII-deficient  mice  although  the
pericyte and endothelial cell loss was significantly inhibited.
This observation could lead to the conclusion that other factors
apart from the net cellular loss contribute to the formation of
acellular capillaries.
In conclusion, our data indicate that the proinflammatory
cytokine TNF-α plays a major role in endothelial and retinal
cell injury and apoptosis during diabetes. TNF-α is involved
in endothelial apoptosis directly via death receptor-mediated
apoptosis and indirectly via an increased leukostasis. Together
with our previous data demonstrating the role of TNF-α on
diabetic vascular leakage [14], we can conclude from this
study that TNF-α is one of the major cytokines in diabetic
retinopathy both involved in leukocyte activation as well as
in endothelial cell apoptosis. The inhibition of both initiation-
and execution-caspase activation in the diabetic model by
etanercept demonstrates the potential of the TNF-α antagonist
to  inhibit  diabetic  apoptosis,  including  the  death-inducing
signaling  complex.  However,  the  exact  death  receptor
pathways either triggered by FAS (CD95) or via TNF-RI
remain to be elucidated. Given their established efficacy and
safety profile, biologic agents that neutralize TNF-α have
received  approval  from  the  USA  Food  and  Drug
Administration for the treatment of rheumatoid arthritis [42].
These drugs could be of potential benefit in preventing early
diabetic vascular damage.
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